Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 8;9(6):e002273. doi: 10.1136/jitc-2020-002273

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Features of TLS are Associated with OS. Kaplan-Meier curves for the indicated immune markers are shown in A–D. (A) Prolonged OS is associated with TLS^pos metastases (median 21.9 months) vs TLS^neg (median 8.0 months); (B) prolonged OS is associated with a high fraction of CD20⁺ B-cells expressing aid, median 29.5 vs 10.5 months; (C) prolonged os is associated with low fraction of CD8⁺ T-cells expressing EOMES, median 29.8 vs 15.2 months; (D) prolonged OS correlates with low fraction of CD20⁺ B-cells coexpressing CD21, median OS=29.5 vs 10.5 months. OS, overall survival; TLS, tertiary lymphoid structure.